Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) Sees Large Decline in Short Interest
Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) Sees Large Decline in Short Interest
Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH – Get Rating) was the target of a large decrease in short interest in September. As of September 15th, there was short interest totalling 7,460,000 shares, a decrease of 5.1% from the August 31st total of 7,860,000 shares. Based on an average trading volume of 891,900 shares, the short-interest ratio is presently 8.4 days. Approximately 15.9% of the shares of the company are short sold.
納斯達克(Deciphera PharmPharmticals，Inc.)(DCPH-GET評級)是空頭股數9月份大幅下跌的目標。截至9月15日，空頭股數共有746萬股，比8月31日的786萬股減少了5.1%。以平均成交量891,900股計算，目前短息比率為8.4天。該公司約15.9%的股份被賣空。
Hedge Funds Weigh In On Deciphera Pharmaceuticals
對衝基金參與Deciphera PharmPharmticals
Institutional investors have recently bought and sold shares of the business. Goldman Sachs Group Inc. grew its stake in shares of Deciphera Pharmaceuticals by 739.6% during the fourth quarter. Goldman Sachs Group Inc. now owns 3,635,510 shares of the company's stock worth $35,519,000 after purchasing an additional 3,202,527 shares during the period. Canada Pension Plan Investment Board bought a new stake in shares of Deciphera Pharmaceuticals in the fourth quarter valued at about $10,772,000. Federated Hermes Inc. lifted its holdings in shares of Deciphera Pharmaceuticals by 125.5% in the first quarter. Federated Hermes Inc. now owns 1,959,078 shares of the company's stock valued at $18,161,000 after purchasing an additional 1,090,368 shares in the last quarter. BlackRock Inc. lifted its holdings in shares of Deciphera Pharmaceuticals by 27.6% in the first quarter. BlackRock Inc. now owns 4,845,376 shares of the company's stock valued at $44,917,000 after purchasing an additional 1,047,807 shares in the last quarter. Finally, Deerfield Management Company L.P. Series C lifted its holdings in shares of Deciphera Pharmaceuticals by 12.0% in the second quarter. Deerfield Management Company L.P. Series C now owns 6,250,964 shares of the company's stock valued at $82,200,000 after purchasing an additional 670,508 shares in the last quarter. Institutional investors own 72.29% of the company's stock.
機構投資者最近買賣了該公司的股票。去年第四季度，高盛在Deciphera PharmPharmticals的持股增加了739.6%。高盛股份有限公司在此期間增持了3,202,527股，目前持有該公司3,635,510股股票，價值35,519,000美元。加拿大養老金計劃投資委員會在第四季度購買了Deciphera製藥公司的新股份，價值約10,772,000美元。聯合愛馬仕公司在第一季度增持了125.5%的Deciphera PharmPharmticals股票。聯合愛馬仕公司目前持有1,959,078股該公司股票，價值18,161,000美元，上一季度又購買了1,090,368股。今年第一季度，貝萊德增持了Deciphera PharmPharmticals的股份，增持幅度為27.6%。貝萊德股份有限公司在上個季度購買了1,047,807股後，目前持有該公司4,845,376股股票，價值44,917,000美元。最後，Deerfield Management Company L.P.Series C在第二季度增持了Deciphera PharmPharmticals的股票12.0%。Deerfield Management Company L.P.C系列現在擁有該公司6,250,964股股票，價值82,200,000美元，上個季度又購買了670,508股。機構投資者持有該公司72.29%的股票。
Analyst Upgrades and Downgrades
分析師升級和下調評級
DCPH has been the topic of several analyst reports. Piper Sandler increased their target price on Deciphera Pharmaceuticals from $13.00 to $18.00 in a research report on Sunday, September 11th. JMP Securities raised Deciphera Pharmaceuticals from a "market perform" rating to an "outperform" rating and set a $23.00 target price for the company in a research note on Friday, August 5th. Cowen started coverage on Deciphera Pharmaceuticals in a research note on Monday, August 29th. They set an "outperform" rating and a $25.00 target price for the company. SVB Leerink upped their target price on Deciphera Pharmaceuticals from $21.00 to $25.00 and gave the company an "outperform" rating in a report on Monday, September 12th. Finally, Stifel Nicolaus upped their target price on Deciphera Pharmaceuticals from $11.00 to $18.00 and gave the company a "hold" rating in a report on Tuesday, September 27th. Two equities research analysts have rated the stock with a sell rating, five have given a hold rating and five have given a buy rating to the company. According to MarketBeat, Deciphera Pharmaceuticals currently has a consensus rating of "Hold" and an average price target of $18.70.
DCPH一直是幾份分析師報告的主題。派珀·桑德勒在9月11日週日的一份研究報告中將Deciphera PharmPharmticals的目標價從13.00美元上調至18.00美元。JMP Securities在8月5日(週五)的一份研究報告中將Deciphera PharmPharmticals的評級從“市場表現”上調至“表現優於大盤”，併為該公司設定了2300美元的目標價。考恩在8月29日星期一的一份研究報告中開始報道Deciphera製藥公司。他們為該公司設定了“跑贏大盤”的評級和25.00美元的目標價。SVB Leerink在9月12日週一的一份報告中將Deciphera PharmPharmticals的目標價從21.00美元上調至25.00美元，並給予該公司“跑贏大盤”的評級。最後，Stifel Nicolaus在9月27日週二的一份報告中將Deciphera PharmPharmticals的目標價從11.00美元上調至18.00美元，並給予該公司“持有”評級。兩名股票研究分析師對該股的評級為賣出，五名分析師給予該公司持有評級，五名分析師給予該公司買入評級。根據MarketBeat，Deciphera PharmPharmticals目前的共識評級為持有，平均目標價為18.70美元。
Deciphera Pharmaceuticals Stock Up 5.0 %
Deciphera製藥類股上漲5.0%
Deciphera Pharmaceuticals (NASDAQ:DCPH – Get Rating) last announced its quarterly earnings data on Thursday, August 4th. The company reported ($0.60) earnings per share for the quarter, topping the consensus estimate of ($0.65) by $0.05. The company had revenue of $32.49 million for the quarter, compared to analyst estimates of $30.11 million. Deciphera Pharmaceuticals had a negative return on equity of 74.37% and a negative net margin of 231.99%. Deciphera Pharmaceuticals's revenue for the quarter was up 37.8% compared to the same quarter last year. During the same quarter last year, the firm earned ($1.21) EPS. As a group, analysts anticipate that Deciphera Pharmaceuticals will post -2.5 earnings per share for the current year.
Deciphera製藥(納斯達克：DCPH-GET評級)最近一次公佈季度收益數據是在8月4日星期四。該公司公佈本季度每股收益(0.60美元)，比普遍預期的(0.65美元)高出0.05美元。該公司本季度營收為3,249萬美元，而分析師預期為3,011萬美元。Deciphera製藥公司的淨資產回報率為負74.37%，淨利潤率為負231.99%。與去年同期相比，Deciphera製藥公司本季度的收入增長了37.8%。去年同期，該公司每股收益為1.21美元。作為一個整體，分析師預計Deciphera製藥公司本年度的每股收益將為2.5%。
About Deciphera Pharmaceuticals
關於Deciphera製藥公司
(Get Rating)
(獲取評級)
Deciphera Pharmaceuticals, Inc, a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally. Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST), as well as in INTRIGUE Phase 3 study to treat second-line GIST.
生物製藥公司Deciphera PharmPharmticals，Inc.通過解決美國和國際上限制對現有癌症療法反應的速度和持久性的關鍵耐藥機制，開發改善癌症患者生命的藥物。它的主要候選藥物是用於治療胃腸道間質瘤(GIST)的QINLOCK，以及用於治療二線GIST的3期試驗。
See Also
另請參閲
- Get a free copy of the StockNews.com research report on Deciphera Pharmaceuticals (DCPH)
- Archer Daniels Midland: Dividend Hero With 49 Years Of Increases
- Will Fully Autonomous Tractors Make Deere the Tesla of Farming?
- Magna International is Your Auto and EV One-Stop Shop Stock
- EV Battery Maker Freyr Set For Major Global Expansion
- MarketBeat: Week in Review 9/26 – 9/30
- 免費獲取StockNews.com關於Deciphera製藥的研究報告(DCPH)
- 阿徹·丹尼爾斯·米德蘭：49年增長的紅利英雄
- 全自動拖拉機會讓迪爾成為農業領域的特斯拉嗎？
- 麥格納國際是您的汽車和電動汽車一站式庫存
- 電動汽車電池製造商Freyr將在全球大舉擴張
- MarketBeat：回顧一週9/26-9/30
Receive News & Ratings for Deciphera Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Deciphera Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
獲得《Deciphera PharmPharmticals Daily》的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對Deciphera製藥公司和相關公司的最新新聞和分析師評級的每日簡要摘要。